You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Login
Username:

Password:


Related Headlines

DATROWAY receives US priority review for first-line metastatic triple negative breast cancer

Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil

Natera submits Signatera CDx PMA to FDA for bladder cancer use

Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer

I Peace generates human iPS cells from NKT cells and offers them for research use

Frontage expands early phase clinical research capabilities across US and China

AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC

Formation Bio acquires worldwide rights to FHND5032 from CTFH

Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA

Almirall receives China approval for Seysara to treat moderate-to-severe acne

Alvotech reaches global settlement over aflibercept biosimilar patents

OSE Immunotherapeutics prioritises pouchitis and hidradenitis suppurativa for lusvertikimab development

InSysBio agrees new collaborative project with BeOne Medicines

WuXi Biologics collaborates with Sinorda Biomedicine for antibody development

Physiomics secures new modelling contract with Numab Therapeutics

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026